IDEAYA Halts Phase 3 Eye Cancer Trial, Frees $100-125M for ADC Push
IDYA sits 18% above its 52-week low of $26.81.
Summary
IDEAYA closed out Q3 with $1.15 billion in cash and kept its runway guidance into 2030 unchanged, but the bigger news is the decision to stop enrollment and shut the Phase 3 OptimUM-010 trial in neoadjuvant uveal melanoma due to site activation and enrollment problems. Management expects that to free up $100-125 million, which it will redirect to potential registrational trials for IDE849 and IDE892. The darovasertib NDA in metastatic uveal melanoma was submitted in Q3 under the FDA's Real-Time Oncology Review program, and ESMO data presented in October support the combination across HLA status and lines of therapy. Quarterly R&D rose to $121.6 million from $108.7 million and the net loss widened to $125.7 million from $112.5 million, with a loss per share of $1.22 and revenue of $10.2 million, so spending is climbing even as one late-stage program is cut. The company also promoted Dr. Michael White to President, Research and Development, and will host an R&D Day in London on November 16, 2026 to lay out the MTAP/CDKN2A combination strategy with RAS inhibitors.
At the time of this announcement, IDYA was trading at $31.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $26.81 to $42.68. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.